Sandbox:ab

WikiDoc Resources for Sandbox:ab
Articles
Most recent articles on Sandbox:ab Most cited articles on Sandbox:ab Review articles on Sandbox:ab Articles on Sandbox:ab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sandbox:ab Images of Sandbox:ab Photos of Sandbox:ab Podcasts & MP3s on Sandbox:ab Videos on Sandbox:ab
Evidence Based Medicine
Cochrane Collaboration on Sandbox:ab Bandolier on Sandbox:ab TRIP on Sandbox:ab
Clinical Trials
Ongoing Trials on Sandbox:ab at Clinical Trials.gov Trial results on Sandbox:ab Clinical Trials on Sandbox:ab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sandbox:ab NICE Guidance on Sandbox:ab NHS PRODIGY Guidance FDA on Sandbox:ab CDC on Sandbox:ab
Books
Books on Sandbox:ab
News
Sandbox:ab in the news Be alerted to news on Sandbox:ab News trends on Sandbox:ab
Commentary
Blogs on Sandbox:ab
Definitions
Definitions of Sandbox:ab
Patient Resources / Community
Patient resources on Sandbox:ab Discussion groups on Sandbox:ab Patient Handouts on Sandbox:ab Directions to Hospitals Treating Sandbox:ab Risk calculators and risk factors for Sandbox:ab
Healthcare Provider Resources
Symptoms of Sandbox:ab Causes & Risk Factors for Sandbox:ab Diagnostic studies for Sandbox:ab Treatment of Sandbox:ab
Continuing Medical Education (CME)
CME Programs on Sandbox:ab
International
Sandbox:ab en Espanol Sandbox:ab en Francais
Business
Sandbox:ab in the Marketplace Patents on Sandbox:ab
Experimental / Informatics
List of terms related to Sandbox:ab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

• In Italy, for the first time in a 69-year-old patient, who was presented with cardiogenic shock due to COVID-19 infection, myocardial involvement by viral particles was pathologically proved through biopsy.

Classification

There is no specific classification for COVID-19 associated cardiogenic shock. For more information regarding general classification, see the cardiogenic shock classification.

Pathophysiology

Two mechanisms are more probable to contribute to cardiogenic shock related to Covid-19:

• Direct invasion of the virus into the cardiomyocytes
• Cytokine storm activated by T helper cells (Th1 and Th2) and trigger a systemic hyperinflammatory response.

Differentiating COVID-19 associated cardiogenic shock from other Diseases

• Cardiogenic shock related to COVID-19 must be differentiated from other diseases when hemodynamics not changing, such as:

• COVID-19 associated distributive shock
• COVID-19 associated hypovolemic shock
• COVID-19 associated mixed (distributive and cardiogenic shock)

Epidemiology and Demographics

• The prevalence of cardiogenic shock-associated COVID-19 has not yet been reported.
• A 69-year-old patient from Italy has been reported by Tavazzi et al., as a cardiogenic shock-associated COVID-19 case. The patient had flu-like symptoms when he was hospitalized and quickly deteriorated into respiratory distress and cardiogenic shock.

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].